The crucial role of metal ions in neurodegeneration: The basis for a promising therapeutic strategy

British Journal of Pharmacology

Volumn 146, Issue 8, 2005, Pages 1041-1059

  Gaeta, Alessandra ^a   Hider, Robert C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

synuclein; A amyloid; Chelation therapy; Copper; Iron; Neurodegeneration; Oxidative stress; Prion protein; Protein aggregation

Indexed keywords

1,10 PHENANTHROLINE; 2,2' BIPYRIDINE; 8 QUINOLINOL; 8 QUINOLINOL DERIVATIVE; ALPHA SYNUCLEIN; AMYLOID; AMYLOID BETA PROTEIN; BATHOCUPROINE; CARBOXYLIC ACID DERIVATIVE; CHELATING AGENT; CLIOQUINOL; DEFERIPRONE; DEFEROXAMINE; DP 109; FERALEX; HYDRAZINE DERIVATIVE; HYDROGEN PEROXIDE; IRON CHELATING AGENT; IRON COMPLEX; ISONICOTINOYLPICOLINOYLHYDRAZINE; MANGANESE; METAL ION; NEUROMELANIN; PHENANTHROLINE DERIVATIVE; PLACEBO; PRION PROTEIN; PYRIDONE DERIVATIVE; QUINOLINOL DERIVATIVE; SYNUCLEIN; UNCLASSIFIED DRUG; VK 28;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CHELATION THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DISEASE TRANSMISSION; HUMAN; IRON OVERLOAD; LIPID PEROXIDATION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; REVIEW; RISK FACTOR;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CHELATING AGENTS; COPPER; HUMANS; IONS; IRON; MANGANESE; METALS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PARKINSON DISEASE; PRION DISEASES; PRIONS; PROTEINS;

EID: 29044438902     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706416     Document Type: Review

References (174)

1. ABEYSINGHE, R.D., ROBERTS, P.J., COOPER, C.E., MACLEAN, K.H., HIDER, R.C. & PORTER, J.B. (1996). The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators. J. Biol. Chem., 271, 7965-7972.
2. ADAMS, J.H., CORSELLIS, J.A.N. & DUNCHEN, L.W. eds. (1984). Greenfield's Neuropathology, 4th edn. New York: Wiley.
3. ALAM, Z.I., DANIEL, S.E., LEES, A.J., MARSDEN, D.C., JENNER, P. & HALLIWELL, B. (1997). A generalised increase in protein carbonyls in the brain of Parkinson's but not incidental Lewy body disease. J. Neurochem., 69, 1326-1329.
4. ALPER, G. & NARAYANAN, V. (2003). Friedreich's ataxia. Ped. Neurol., 28, 335-341.
5. ANTZUTKIN, O.N., LEAPMAN, R.D., BALBACH, J.J. & TYCKO, R. (2002). Sopraraolecular structural constraints on Alzheimer's β-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry, 41, 15436-15450.
6. ATWOOD, C.S., OBRENOVICH, M.E., LIU, T., CHAN, H., PERRY, G., SMITH, M.A. & MARTINS, R.N. (2003). Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res. Rev., 43, 1-16.
7. BABCOCK, M., DE SILVA, D., OAKS, R., DAVIS-KAPLAN, S., JIRALERSPONG, S., MONTERMINI, L., PANDOLFO, M. & KAPLAN, J. (1997). Regulation of mitochondrial iron accumulation by Yfh1p, a putative homologue of frataxin. Science, 276, 1709-1712.
8. BELLINGER-KAWAHARA, C.G., KEMPNER, E., GROTH, D., GABIZON, R. & PRUSINER, S.B. (1988). Scrapie prion liposomes and rods exhibit target sizes of 55,000 Da. Virology, 164, 537-541.
9. BENCE, N.F., SAMPAT, R.M. & KOPITO, R.R. (2001). Impairment of the ubiquitin-proteosome system by protein aggregation. Science, 292, 1552-1555.
10. BEN-SHACHAR, D., KAHANA, N., KAMPEL, V., WARSHAWSKY, A. & YOUDIM, M.B.H. (2004). Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology, 46, 254-263.
11. BEN-SHACHAR, D., RIEDERER, P. & YOUDIM, M.B. (1991). Iron melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem., 57, 1609-1614.
12. BENSIMON, G., LACOMBLEZ, L. & MEININGER, V. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N. Engl. J. Med., 330, 585-591.
13. BONILLA, E. (2000). Huntington disease. A review. J. Clin. Invest., 41, 117-141.
14. BRADLEY, J.L., BLAKE, J.C., CHAMBERLAIN, S., THOMAS, P.K., COOPER, J.M. & SCHAPIRA, A.H.V. (2000). Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Gen., 9, 275-282.
15. BRINDELLI, M.G., TAMPELLINI, D. & ZECCA, L. (1999). The structure of neuromelanin and its iron binding site studied by infrared spectroscopy. FEBS Lett., 457, 18-22.
16. BRION, S., MIROL, J. & PSIMARAS, A. (1973). Recent findings in Pick's disease. In: Progress in Neuropathology, ed. Zimmerman, H.M., Vol. 2, pp. 421-452. New York: Grune and Stratton.
17. BROWN, D.R. (2001). Copper and prion disease. Br. Res. Bull., 55, 165-173.
18. BROWN, D.R., GUATIERI, V., GRASSO, G., IMPELLIZZERI, G., PAPPALARDO, G. & RIZZARELLI, E. (2004). Copper(II) complexes of peptide fragments of the prion protein. Conformation changes induced by copper(II) and the binding motif in C-terminal protein region.. J. Inorg. Biochem., 98, 133-143.
19. BROWN, D.R., HAFIZ, F., GLASSMITH, L.L., WONG, B.-S., JONES, I.M., CLIVE, C. & HASWELL, S.J. (2000). Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J., 19, 1180-1186.
20. BROWN, D.R., QUIN, K., HERMS, J.W., MADLUNG, A., MANSON, J., STROIME, R., FRASER, P.E., KRUCK, T.A., VON BOHLEN, A., SCHULZ-SCHAEFFER, W., GIESE, A., WESTAWAY, D. & KRETZSCHMAR, H. (1997a). The cellular prion protein binds copper in vivo. Nature, 390, 684-687.
21. BROWN, D.R., SCHULZ-SCHAEFFER, W.J., SCHMIDT, B. & KRETZSCHMAR, H.A. (1997b). Prion protein-deficient cells show altered response to oxidative stress due to decreases SOD-1 activity. Exp. Neurol., 146, 104-112.
22. BRUNK, U.T., JONES, C.B. & SOHAL, R.S. (1992). A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. Mut. Res., 275, 395-403.
23. BRUNK, U.T. & TERMAN, A. (2002). Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Rad. Biol. Med., 33, 611-619.
24. BUCCIANTINI, M., GIANNONI, F., CHITI, F., BARONI, F., FORMIGLI, L., ZURDO, J.S., TADDEI, N., RAMPONI, G., DOBSON, C.M. & STEFANI, M. (2002). Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature, 416, 501-511.
25. BÜELER, H., AGUZZI, A., SAILER, A., GREINER, R.-A., AUTENRIED, P., AUGET, M. & WEISSMAN, C. (1993). Mice devoid of PrP are resistant to scrapie. Cell, 73, 1339-1347.
26. BUSH, A.I. (2002). Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Ageing, 23, 1031-1038.
27. BUSH, A.I., HUANG, X. & FAIRLIE, D.P. (1999). The possible origin of free radicals from amyloid β-peptides in Alzheimer's disease. Neurobiol. Ageing, 20, 335-337.
28. BUTTERFIELD, D.A., DRAKE, J., POCERNICH, C. & CASTEGNA, A. (2001). Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol. Med., 7, 548-554.
29. BUTTERFIELD, D.A. & KANSKI, J. (2001). Brain oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev., 122, 945-962.
30. CAMPUZANO, V., MONTERMINI, L., MOLTÒ, M.D., PIANESE, L., COSSÉE, M., CAVALCANTI, F., MONROS, E., RODIUS, F.F., DUCLOS MONTICELLI, A., ZARA, F., CAÑIZARES, J., KOUTNIKOVA, H., BIDICHANDANI, S.I., GELLERA, C., BRICE, A., TROUILLAS, P., DE MICHELE, G., FILLA, A., DE FRUTOS, R., PALAU, F., PATEL, P.I., DI DONATO, S., MANDEL, J.-L., COCOZZA, S., KOENIG, M. & PANDOLFO, M. (1996). Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science, 271, 1423-1427.
31. CARRÌ, M.T., FERRI, A., COZZOLINO, M., CALABRESE, L. & ROTILIO, G. (2003). Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Br. Res. Bull., 61, 365-374.
32. CHERNY, R.A., ATWOOD, C.S., XILINAS, M.E., GRAY, D.N., JONES, W.D., MCLEAN, C.A., BARNHAM, K.J., VOLITAKIS, I., FRASER, F.W. & KIM, Y.-S. (2001). Treatment with a copper-zinc chelator markedly and rapidly inhibits b-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 30, 665-676.
33. CHERNY, R.A., BARNHAM, K.J., LYNCH, T., VOLITAKIS, I., LI, Q.-X., MCLEAN, C.A., MULTHAUP, G., BEYREUTHER, K., TANZI, R.E., MASTERS, C.L. & BUSH, A.I. (2000). Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J. Struct. Biol., 130, 209-216.
34. CHETLEY, A. & GILBERT, D. (1986). Health Action International. The Hangue: International Organisation of Consumers Unions.
35. CHEUN, W.L. (2004). The chemical structure of melanin. Pigm. Cell Res., 17, 422-424.
36. CLAESEN, M.E. & CLEMENTS, M.L. (1989). Ridding the world of hydroxyquinolines. Br. Med. J., 299, 527-528.
37. COHEN, A.S., SHIRAHAMA, T. & SKINNER, M. (1982). Electron microscopy of amyloid. In: Electron Microscopy of Proteins. ed. Harris, J.R., Vol. 3, pp. 165-205. London, UK: Academic Press.
38. COHEN, F.E. (1999). Protein misfolding and prion diseases. J. Mol. Biol., 293, 313-320.
39. COMPSTON, A. & COLES, A. (2002). Multiple sclerosis. Lancet, 359, 1221-1231.
40. CONFAVREUX, C., AIMARD, G. & DEVIC, M. (1980). Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain, 103, 281-300.
41. CONNOR, J.R., SNYDER, B.S., AROSIO, P., LOEFFLER, D.A. & LEWITT, P. (1995). A quantitative analysis of isoferritins in select regions of aged, parkinsonian and Alzheimer's diseased brains. J. Neurochem., 65, 717-724.
42. CONWAY, K.A., BAXTER, E.W., FELSENSTEIN, K.M. & REITZ, A.B. (2003). Emerging β-amyloid therapies for the treatment of Alzheimer's disease. Curr. Pharm. Des., 9, 427-447.
43. CONWAY, K.A., HARPER, J.D. & LANSBURY, P.T. (1998). Accelerated in vitro fibril formation by mutant α-synuclein linked to early-onset Parkinson's disease. Nat. Med., 4, 1318-1320.
44. COOPER, C.E., LYNAGH, G.R., HOYES, K.P., HIDER, R.C., CAMMACK, R. & PORTER, J.B. (1996). The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem., 271, 20291-20299.
45. CRAPPER MCLACHLAN, D.R., DALTON, A.J., KRUCK, T.P.A., BELL, M., SMITH, W., KALOW, W. & ANDREWS, D.F. (1991). Effect of desferrioxamine on the clinical progress of Alzheimer's disease. Lancet, 337, 1304-1308.
46. DE FELICE, F.G. & FERREIRA, S.T. (2002). β-Amyloid production, aggregation and clearance as targets for therapy in Alzheimer's disease. Cell. Mol. Neurobiol., 22, 545-563.
47. DEXTER, D.T., WELLS, F.R. & LEES, A.J. (1989). Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem., 52, 381-389.
48. DICKSON, D.W., CRYSTAL, H.A., BEVONA, C., HONER, W., VINCENT, I. & DAVIES, P. (1995). Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging, 16, 285-298.
49. DOBSON, M.C. (2003a). Protein folding and disease: a view from the first Horizon Symposium. Nat. Drug Disc., 2, 154-160.
50. DOBSON, M.C. (2003b). Protein folding and misfolding. Nature, 426, 884-890.
51. DOUBLE, K.L., GERLACH, M., BEN-SHACHAR, D., YOUDIM, M.B.H., ZECCA, L. & RIEDERER, P. (2002). Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotox. Teratol., 24, 621-628.
52. DOUBLE, K.L., GERLACH, M., SCHÜNEMANN, V., TRAUTWEIN, A.X., ZECCA, L., GALLORINI, M., YOUDIM, M.B.H., RIEDERER, P. & BEN-SHACHAR, D. (2003). Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol., 66, 489-494.
53. DOUBLE, K.L., RIEDERER, P.F. & GERLACH, M. (1999). Significance of neuromelanin for neurodegeneration in Parkinson's disease. Drug News Dev., 12, 333-340.
54. DOUBLE, K.L., ZECCA, L., COSTI, P., MAUER, M., GRIESINGER, C., ITO, S., BEN-SHACHAR, D., BRINGMANN, G., FARIELLO, R.G., RIEDERER, P. & GERLACH, M. (2000). Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J. Neurochem., 75, 2583-2589.
55. DUFFY, P.E. & TENNYSON, V.M. (1965). Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and Locus caeruleus in Parkinson's disease. J. Neuropathol. Exp. Neurol., 24, 398-414.
56. 53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett., 440, 67-70.
57. FINEFROCK, A.E., BUSH, A.I. & DORAISWAMY, P.M. (2003). Current status of metals as therapeutic targets in Alzheimer's disease. J. Am. Geriatr. Soc., 51, 1143-1148.
58. FLOYD, R.A. (1999). Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med., 222, 236-245.
59. FLOYD, R.A. & HENSLEY, K. (2002). Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol. Aging, 23, 795-807.
60. GHETTI, B., PICCARDO, P., FRANGIONE, B., BUGIANI, O., GIACCONE, G., YOUNG, K., PRELLI, F., FARLOW, M.R., DLOUHY, S.R. & TAGLIAVINI, F. (1996). Prion protein amyloidosis. Brain Pathol., 6, 127-145.
61. GOTZ, M.E., KÜNIG, G., RIEDERER, P. & YOUDIM, M.B.H. (1994). Oxidative stress: free radical production in neural degeneration. Pharmacol. Ther., 63, 37-122.
62. GUENTCHEV, M., VOIGTLÄNDER, T., HABERLER, C., GROSCHUP, M.H. & BUDKA, H. (2000). Evidence for oxidative stress in experimental prion disease. Neurobiol. Dis., 7, 270-273.
63. HABGOOD, M.D., LIU, Z.D., DEHKORDI, L.S., KHODR, H.H., ABBOTT, J. & HIDER, R.C. (1999). Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability. Biochem. Pharmacol., 57, 1305-1310.
64. HALLIWELL, B. (1992). Reactive oxygen species and the central nervous system. J. Neurochem., 59, 1609-1623.
65. HARDY, J. & SELKOE, D.J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297, 353-356.
66. HARRIS, D.A. (2001). Biosynthesis and cellular processing of the prion protein. Advan. Protein Chem., 57, 203-228.
67. HARRIS, D.C. & AISEN, P. (1973). Facilitation of Fe(II) autoxidation by Fe(III) complexing agents. Biochim. Biophys. Acta, 329, 156-158.
68. HARTLEY, D.M., WALSH, D.M., YE, C.P., DIEHL, T., VASQUEZ, S., VASSILEV, P.M., TEPLOW, D.B. & SELKOE, D.J. (1999). Protofibrillar intermediates of amyloid b-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurones. J. Neurosci., 19, 8876-8884.
69. HEDGE, M.L. & JAGANNATHA RAO, K.S. (2003). Challenges and complexities of α-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease. Arch. Biochem. Biophys., 418, 169-178.
70. HELY, M.A., FUNG, V.S. & MORRIS, J.G. (2000). Treatment of Parkinson's disease. J. Clin. Neurosci., 7, 484-494.
71. HIDER, R.C. (1995). Potential protection from toxicity by oral iron chelators. Toxicol. Lett., 82-83, 961-967.
72. HIDER, R.C. & HALL, A.D. (1991). Clinically useful chelators of tripositive elements. Prog. Med. Chem., 28, 41-173.
73. C may inhibit prion disease propagation. Br. Res., 993, 192-200.
74. HIRSH, E.C., BRANDEL, J.-P. & GALLE, P. (1991). Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem., 56, 446-451.
75. HOLANDER, D., RICKETTS, D. & BOYD, C.A.R. (1988). Importance of probe molecular geometry in determining intestinal permeability. Can. J. Gastroenterol., 2, 35A-38A.
76. HSIAO, K., CHAPMAN, P., NILSEN, S., ECKMAN, C., HARIGAYA, Y., YOUNKIN, S., YANG, F. & COLE, G. (1996). Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science, 274, 99-102.
77. HUANG, X., ATWOOD, C.S., HARTSHORN, M.A., MULTHAUP, G., GOLDSTEIN, L.E., SCARPA, R.C., CUAJUNGCO, M.P., GRAY, D.N., LIM, J., MOIR, R.D., TANZI, R.E. & BUSH, A.I. (1999). The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry, 38, 7609-7616.
78. JEFFREY, M., GOODSIR, C.M., BRUCE, M.E., MCBRIDE, P.A. & SCOTT, J.R. (1994). Infection-specific prion protein (PrP) accumulates on neuronal plasmalemma in scrapie-infected mice. Ann. NY Acad. Sci., 724, 327-330.
79. JELLIGER, K.A. (1999). The role of iron in neurodegeneration: prospects for pharmacology of Parkinson's disease. Drugs Aging, 14, 115-140.
80. KASTNER, A., HIRSCH, E.C. & LEJEUNE, O. (1992). Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem., 59, 1080-1089.
81. KAUR, D., YANTIRI, F., RAJAGOPALAN, S., KUMAR, J., MO, J.Q., BOONPLUEANG, R., VISWANATH, V., JACOBS, R., YANG, L., BEAL, M.F., DI MONTE, D., VOLITASKIS, I., ELLERBY, L., CHERNY, R.A., BUSH, A.I. & ANDERSON, J.K. (2003). Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron, 37, 899-909.
82. KEEGAN, B.M. & NOSEWORTHY, J.H. (2002). Multiple sclerosis. Ann. Rev. Med., 53, 285-302.
83. KIM, N., PARK, S.J., JIN, J.K., KWON, M.S., CHOI, E.K., CARP, R.I. & KIM, Y.S. (2000). Increased ferric iron content and iron-induced oxidative stress in the brains of scrapie-infected mice. Br. Res., 884, 98-103.
84. KLEIN, W.L., KRAFFT, G.A. & FINCH, C.E. (2001). Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci., 24, 219-224.
85. KROPF, A.J., BUNKER, B.A., EISNER, M., MOSS, S.C., ZECCA, L., STROPPOLO, A. & CRIPPA, P.R. (1998). X-ray absorption fine-structure spectroscopy studies of Fe sites in natural human neuromelanin and synthetic analogues. Biophys. J., 75, 3135-3142.
86. KRÜGER, R., KUHN, W., MÜLLER, T., WOITALLA, D., GRABBER, M., KÖSEL, S., PRZUNTEK, H., EPPLEN, J.T., SCHOLS, L. & RIESS, O. (1998). AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet., 18, 106-108.
87. KUKULL, W.A., HIGDON, R., BOWEN, J.D., MCCORMICK, W.C., TERI, L., SCHELLENBERG, G.D., VAN BELLE, G., JOLLEY, L. & LARSON, E.B. (2002). Dementia and Alzheimer disease incidence: a prospective cohort study. Arch. Neurol., 59, 1737-1746.
88. LAHIRI, D.K., FARLOW, M.R., SAMBAMURTI, K., GREIG, N.H., GIACOBINI, E. & SCHNEIDER, L.S. (2003). A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets, 4, 97-112.
89. LAINE, J., MARC, M.-E., SY, M.-S. & AXELRAD, H. (2001). Cellular and subcellular morphological localization of normal prion protein in rodent cerebellum. Eur. J. Neurosci., 14, 47-56.
90. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A., 95, 6448-6453.
91. LAN, J. & JIANG, D.H. (1997). Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm., 104, 469-481.
92. LEE, J.-Y., FRIEDMAN, J.E., ANGEL, L., KOZAK, A. & KOH, J.-Y. (2004). The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice. Neurobiol. Aging, 25, 1315-1321.
93. LEHMANN, S. (2002). Metal ions and prion disease. Curr. Opin. Chem. Biol., 6, 187-192.
94. LIU, Z.D. & HIDER, R.C. (2002a). Design of clinically useful iron(III)-selective chelators. Med. Res. Rev., 22, 26-64.
95. LIU, Z.D. & HIDER, R.C. (2002b). Design of iron chelators with therapeutic application. Coord. Chem. Rev., 232, 151-171.
96. LIU, Z.D., KAYYALI, R., HIDER, R.C., PORTER, J.B. & THEOBALD, A.E. (2002). Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators. J. Med. Chem., 45, 631-639.
97. LIU, Z.D., LOCKWOOD, M., ROSE, S., THEOBALD, A.E. & HIDER, R.C. (2001). Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase. Biochem. Pharmacol., 61, 285-290.
98. LOVELL, M.A., ROBERTSON, J.D., TEESDAL, W.J., CAMPBELL, J.L. & MARKESBERY, W.R. (1998). Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci., 158, 47-52.
99. LUE, L.F., KUO, Y.-M., ROHER, A.E., BRACHOVA, L., SHEN, Y., SUE, L., BEACH, T., KURTH, J.H., RYDEL, R.E. & ROGERS, J. (1999). Soluble amyloid β-peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol., 155, 853-862.
100. MACCHI, G. & CIOFFI, R.P. (1992). An in vivo and post mortem MRI study in multiple sclerosis with pathological correlation. Ital. J. Neurol. Sci., 13, 97-103.
101. MAISSEN, M., ROECKL, C., GLATZEL, M., GOLDMANN, W. & AGUZZI, A. (2001). Plasminogen binds to disease-associated prion protein of multiple species. Lancet, 357, 2026-2028.
102. MANGÉ, A., MILAHAVET, O., UMLAUF, D., HARRIS, D. & LEHMANN, S. (2002). PrP-dependent cell adhesion in N2a neuroblastoma cells. FEBS Lett., 514, 159-162.
103. MARTELL, A.E. & SMITH, R.M. (1974-1989). Critical Stability Constant, Vols. 1-6,. London: Plenum Press.
104. MASON, J.M., KOKKONI, N., STOTT, K. & DOIG, A.J. (2003). Design strategies for anti-amyloid agents. Curr. Opin. Struc. Biol., 13, 526-532.
105. MAXTON, D.G., BJARNASON, I., REYNOLDS, A.P., CATT, S.D., PETERS, T.J. & MENZIES, I.S. (1986). Lactulose, 51Cr-labelled ethylenediaminetetra- acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. Clin. Sci., 71, 71-80.
106. MC GEER, P.L., ITAGAKI, S., BOYES, B.E. & MCGEER, E.G. (1998). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38, 1285-1291.
107. MCLEAN, C.A., CHERNY, R.A., FRASER, F.W., FULLER, S.J., SMITH, M.J., BEYREUTHER, K., BUSH, A.I. & MASTERS, C.L. (1999). Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol., 46, 860-866.
108. MERZ, P.A., SOMMERVILLE, R.A., WISNIEWSKY, H.M. & IKBAL, K. (1981). Abnormal fibrils from scrapie-infected brain. Acta Neuropathol. (Berlin), 54, 63-74.
109. MIRANDA, S., OPAZO, C., LARRONDO, L.F., MUÑOZ, F.J., RUIZ, F., LEIGHTON, F. & INESTROSA, N.C. (2000). The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer's disease. Prog. Neurobiol., 62, 633-648.
110. MIZUNO, Y., OHTA, S., TANAKA, M., TAKAMIYA, S., SUZUKI, K., SATO, T., OYA, H., OZAWA, T. & KAGAWA, Y. (1989). Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun., 163, 1450-1455.
111. MOOSMANN, M. & BEHL, C. (2002). Antioxidants as treatment for neurodegenerative disorders. Exp. Opin. Invest. Drugs, 11, 1407-1435.
112. OAKLEY, G.P. (1973). The neurotoxicity of the halogenated hydroxyquinolines. JAMA, 225, 395-397.
113. OLANOW, C.W. (1992). Magnetic resonance imaging in parkinsonism. Neurol. Clin. North Am., 10, 405-420.
114. OLANOW, C.W. & YOUDIM, M.B. (1996). Neurodegeneration and Neuroprotection in Parkinson's Disease. pp. 55-69. New York: Academic Press.
115. OLDENDORF, W.H. (1974). Lipid solubility and drug penetration of the blood-brain barrier. Proc. Soc. Expt. Bio. Med., 147, 813-816.
116. OLIVIERI, N., KOREN, G., HERMANN, C., BENTUR, Y., CHUNG, D., KLEIN, J., ST LOUIS, P., FREEDMAN, M.H., MCCLELLAND, R.A. & TEMPLETON, D.M. (1990). Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet, 336, 1275-1279.
117. PAIK, S.R., SHIN, H.-J., LEE, J.-H., CHANG, C.-S. & KIM, J. (1999). Copper(II)-induced self-oligomerisation of α-synuclein. Biochem. J., 340, 821-828.
118. PALM, A. (1932). Untersuchung in des chinolin reihe. Arch. Exp. Pathol. Pharmacol., 199, 176-185.
119. PAN, K., BALDWIN, M., NGUYEN, J., GASSET, M., SERBAN, A., GROTH, D., MEHLHORN, I., HUANG, Z., FLETTERICK, R.J., COHEN, F.E. & PRUSINER, S.B. (1993). Conversion of α-helices β-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. U.S.A., 90, 10962-10966.
120. PATTISON, I.H. & JEBBET, J.N. (1971). Histopathological similarities between scrapie and cuprizone toxicity in mice. Nature, 230, 115-117.
121. PEREZ, G.R., WAYMIRE, J.C., LIN, E., LIU, J.J., GUO, F. & ZIGMOND, M.J. (2002). A role for α-synuclein in the regulation of dopamine synthesis. J. Neurosci., 22, 3090-3099.
122. PIEMONTE & VALLE D'AOSTA REGISTER FOR AMYOTROPHIC LATERAL SCLEROSIS (PARALS) (2001). Incidence of ALS in Italy. Evidence for a uniform frequency in Western countries. Neurology, 56, 239-244.
123. POLYMEROPOULOS, M.H., LAVEDAN, C., LEROY, E., IDE, S.E., DEHEJIA, A., DUTRA, A., PIKE, B., ROOT, H., RUBENSTEIN, J., BOYER, R., STENROOS, E.S., CHANDRASEKHARAPPA, S., ATHANASSIADOU, A., PAPAPETROPOULOS, T., JOHNSON, W.G., LAZZARINI, A.M., DUVOISIN, R.C., DI IORIO, G., GOLBE, L.I. & NUSSBAUM, R.L. (1997). Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
124. PRUSINER, S.B. (1982). Novel proteinaceous infectious particles cause scrapie. Science, 216, 136-144.
125. PRUSINER, S.B. (1991). Molecular biology of prion disease. Science, 252, 1515-1522.
126. PRUSINER, S.B. (1998). Prions. Proc. Natl. Acad. Sci. U.S.A., 95, 13363-13383.
127. PRUSINER, S.B. (2001). Neurodegenerative diseases and prions. N. Engl. J. Med., 344, 1516-1526.
128. PRUSINER, S.B., MCKINLEY, M.P., BOWMAN, K.A., BOLTON, D.C., BENDHEIM, P.E., GROTH, D.F. & GLENNER, G.G. (1983). Scrapie prions aggregate to form amyloid-like birefringent rods. Cell, 35, 349-358.
129. RAYMOND, K.N., MÜLLER, G. & MATZANKE, B.F. (1984). Complexation of iron by siderophores: a review of their solution and structural chemistry and biological function. Top Curr. Chem., 58, 49-102.
130. REISBERG, B., DOODY, R., STOFFLER, A., SCHMITT, F., FERRIS, S. & MÖBIUS, H.J. (2003). Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med., 348, 1333-1341.
131. RICHARDSON, D.R. (2004). Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann. NY Acad. Sci., 1012, 326-341.
132. RIEDERER, P., SOFIC, E., RAUSCH, W.D., JELLINGER, K. & YOUDIM, M.B.H. (1989). Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J. Neurochem., 52, 515-520.
133. ROCHET, J.C. & LANSBURY, P.T. (2000). Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol., 10, 60-80.
134. ROHER, A.E., CHANEY, M.O., KUO, Y.-M., WEBSTER, S.D., STINE, W.B., HAVERKAMP, L.J., WOODS, A.S., COTTER, R.J., TUOHY, J.M., KRAFFT, G.A., BONNELL, B.S. & EMMERLING, M.R. (1996). Morphology and toxicity of Aβ-(1-42) dimmer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J.Biol. Chem., 271, 20631-20635.
135. ROSE, F.C. & GAWEL, M. (1984). Clioquinol neurotoxicity: an overview. Acta Neurol. Scand., 80 (Suppl. 100), 137-145.
136. SAGGU, H., COOKSEY, J. & DEXTER, D. (1989). A selective increase in a particular superoxide dismutase activity in Parkinsonian substantia nigra. J. Neurochem., 53, 692-697.
137. SANCHEZ-RAMOS, J., OVERVICK, E. & AMES, B.N. (1994). A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxy-guanoxine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration, 3, 197-204.
138. SERPELL, L.C., BERRIMAN, J., JAKES, R., GOEDERT, M. & CROWTHER, R.A. (2000). Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross β-conformation. Proc. Natl. Acad. Sci. U.S.A., 97, 4897-4902.
139. SHASTRY, B.S. (2003). Neurodegenerative disorders of protein aggregation. Neurochem. Internat., 43, 1-7.
140. SHERKI, Y.G., MELAMED, E. & OFFEN, D. (2001). Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology, 40, 959-975.
141. SHIN, R.-W., KRUCK, T.P.A., MURAYAMA, H. & KITAMOTO, T. (2003). A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer's disease. Br. Res., 961, 139-146.
142. SIKORSKI, P., ATKINS, E.D.T. & SERPELL, L.C. (2003). Structure and texture of fibrous crystals formed by Alzheimer's Aβ (11-25) peptide fragment. Structure, 11, 915-926.
143. SOFIC, E., LANGE, K.W., JELLINGER, K. & RIEDERER, P. (1992). Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett., 142, 128-130.
144. SOFIC, E., RIEDERER, P. & HEINSEN, H. (1988). Increased iron(III) and total iron content in post mortem, substantia nigra of parkinsonian brain. J. Neural Trans., 74, 199-205.
145. STAHL, N., BORCHELT, D.R., HSIAO, K. & PRUSINER, S.B. (1987). Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell, 51, 229-240.
146. SWAN, G.A. (1974). Structure, chemistry and biosynthesis of the melanins. Fortschr. Chem.Org. Naturst, 31, 521-582.
147. TERRY, R.D., MASLIAH, E., SALMON, D.P., BUTTERS, N., DETERESA, R., HILL, R., HANSEN, L.A. & KATZMAN, R. (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 30, 572-580.
148. THACKRAY, A.M., KNIGHT, R., HASWELL, S., BUJDOSO, R. & BROWN, D.R. (2002). Metal imbalance and compromised antioxidant function are early changes in prion disease. Biochem. J., 362, 253-258.
149. TOROK, M., MILTON, S., KAYED, R., WU, P., MCINTIRE, T., GLABE, C.G. & LANGEN, R. (2002). Structural and dynamic features of Alzheimer's Aβ peptide in amyloid fibrils studied by site-directed spin labelling. J. Biol. Chem., 277, 40810-40815.
150. TSUBAKI, T., HONMA, Y. & HOSH, M. (1971). Neurological syndrome associated with clioquinol. Lancet, 1, 696-697.
151. TURNBULL, S., TABNER, B.J., BROWN, R.D. & ALLSOP, D. (2003). Copper-dependent generation of hydrogen peroxide from the toxic prion protein fragment PrP106-126. Neurosci. Lett., 336, 159-162.
152. TURNBULL, S., TABNER, B.J., EL-AGNAF, O.M.A., MOORE, S., DAVIES, Y. & ALLSOP, D. (2001). β-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med., 30, 1163-1170.
153. TWELVES, D., PERKINS, K.S. & COUNSELL, C. (2003). Systematic review of incidence studies of Parkinson's disease. Mov. Disord., 18, 19-31.
154. TYCKO, R. (2004). Progress towards a molecular-level structural understanding of amyloid fibrils. Curr. Opin. Struct. Biol., 14, 1-8.
155. UEDA, K., FUKUSHIMA, H., MASLIAH, E., XIA, Y., IWAI, A., YOSHIMOTO, M., OTERO, D.A.C., KONDO, J., IHARA, Y. & SAITOH, T. (1993). Molecular cloning of cDNA encoding an unrecognised component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A., 90, 11282-11286.
156. UVERSKY, V.N., LI, J. & FINK, A.L. (2001). Metal-triggered structural transformations, aggregation and fibrillation of human α-synuclein. J. Biol. Chem., 276, 10737-10744.
157. VIGO-PELFREY, C., LEE, D., KEIM, P., LIEBERBURG, I. & SCHENK, D.B. (1993). Characterisation of amyloid peptide from human cerebrospinal fluid. J. Neurochem., 61, 1965-1968.
158. WALSH, D.M., HARTLEY, D.M., KUSUMOTO, Y., FEZOUI, Y., CONDRON, M.M., LOMAKIN, A., BENEDEK, G.B., SELKOE, D.J. & TEPLOW, D.B. (1999). Amyloid β protein fibrillogenesis: structure and biological activity of protofibrillar intermediates. J. Biol. Chem., 274, 25945-25952.
159. WALSH, D.M., KLYUBIN, I., FADEEVA, J.V., CULLEN, W.K., ANWYL, R., WOLFE, M.S., ROWAN, M.J. & SELKOE, D.J. (2002). Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416, 535-539.
160. WANG, S.S., BECERRA-ARTEAGA, A. & GOOD, T.A. (2002). Development of a novel diffusion-based method to estimate the size of the aggregated Aβ species responsible for neurotoxicity. Biotechnol. Bioeng., 80, 50-59.
161. WARSHAWSKY, B., YOUDIM, M.B.H. & BEN-SHACAR, D. (2000). Pharmaceutical compositions compromising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators. International Publication number WO 00/74664A2.
162. WEINSHENKER, B.G. (1995). The natural history of multiple sclerosis. Neurol. Clin., 13, 119-146.
163. WEINSHENKER, B.G., BASS, B., RICE, G.P., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J. & EBERS, G.C. (1989). The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain, 112, 133-146.
164. WILMS, H., ROSENSTIEL, P., SIEVERS, J., DEUSCHL, G., ZECCA, L. & LUCIUS, R. (2003). Activation of microglia by human neuromelanin is NF-κB-dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J., 17, 500-502.
165. WISNIEWSKY, H.M., COBLENTZ, J.M. & TERRY, R.D. (1972). Pick's disease. A clinical and ultrastructural study. Arch. Neurol., 26, 97-108.
166. WORLD HEALTH ORGAN (WHO) TECH REP SER (1977). The selection of essential drugs: report of a WHO expert committee. 615, 1-36.
167. XU, J., KAO, S.-Y., LEE, F.J.S., SONG, W., JIN, L.-W. & YANKNER, B.A. (2002). Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med., 8, 600-606.
168. YE, F.Q., ALLEN, P.S. & MARTIN, W.R.W. (1996). Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. Mov. Disord., 11, 243-249.
169. YOKEL, R.A., FREDENBURG, A.M., MEURER, K.A. & SKINNER, T.L. (1995). Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators. Drug Metab. Dispos., 23, 1178-1180.
170. YOUDIM, M.B.H. (1994). The enigma of neuromelanin in Parkinsonian substantia nigra. J. Neural. Transm., 43 (Suppl.), 113-122.
171. ZECCA, L., FARIELLO, R., RIEDERER, P., SULZER, D., GATTI, A. & TAMPELLINI, D. (2002). The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett., 510, 216-220.
172. ZECCA, L., GALLORINI, M., SCHÜNEMANN, V., TRAUTWEIN, A.X., GERLACH, M., RIEDERER, P., VEZZONI, P. & TAMPELLINI, D. (2001a). Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem., 76, 1766-1773.
173. ZECCA, L., TAMPELLINI, D., GERLACH, M., RIEDERER, P., FARIELLO, R.G. & SULZER, D. (2001b). Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. J. Clin. Pathol: Mol. Pathol., 54, 414-418.
174. ZECCA, L., ZUCCA, F.A., WILMS, H. & SULZER, D. (2003). Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic